Virtu Financial LLC purchased a new stake in Genomic Health (NASDAQ:GHDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 7,622 shares of the medical research company’s stock, valued at approximately $261,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Citadel Advisors LLC increased its holdings in Genomic Health by 269.5% in the third quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock valued at $3,010,000 after purchasing an additional 68,418 shares during the last quarter. Wells Fargo & Company MN grew its stake in Genomic Health by 12.8% in the third quarter. Wells Fargo & Company MN now owns 68,884 shares of the medical research company’s stock valued at $2,211,000 after acquiring an additional 7,809 shares during the period. OxFORD Asset Management LLP acquired a new position in Genomic Health in the third quarter valued at about $307,000. Russell Investments Group Ltd. grew its stake in Genomic Health by 38.5% in the third quarter. Russell Investments Group Ltd. now owns 22,670 shares of the medical research company’s stock valued at $727,000 after acquiring an additional 6,304 shares during the period. Finally, Dupont Capital Management Corp acquired a new position in Genomic Health in the fourth quarter valued at about $1,103,000. Hedge funds and other institutional investors own 89.99% of the company’s stock.
Shares of NASDAQ GHDX traded down $1.09 during trading hours on Friday, reaching $30.93. 126,975 shares of the stock were exchanged, compared to its average volume of 177,629. The firm has a market cap of $1,092.57, a P/E ratio of 3,093.00 and a beta of 0.63. Genomic Health has a 52 week low of $26.54 and a 52 week high of $37.50.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Thursday, March 8th. The medical research company reported $0.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($0.01). The company had revenue of $87.50 million for the quarter, compared to analyst estimates of $88.96 million. Genomic Health had a negative return on equity of 0.83% and a negative net margin of 1.13%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.04 EPS. research analysts predict that Genomic Health will post 0.43 earnings per share for the current fiscal year.
In related news, insider Kimberly J. Popovits sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $32.93, for a total transaction of $329,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $35.51, for a total value of $177,550.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,942 shares of company stock worth $1,347,495. Company insiders own 46.20% of the company’s stock.
A number of research analysts have issued reports on the company. BidaskClub raised Genomic Health from a “hold” rating to a “buy” rating in a research note on Friday, March 30th. Zacks Investment Research cut Genomic Health from a “hold” rating to a “strong sell” rating in a research report on Friday, March 9th. Piper Jaffray reaffirmed a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a research report on Thursday, March 8th. ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Finally, Canaccord Genuity reissued a “buy” rating and set a $42.00 price target on shares of Genomic Health in a research report on Tuesday, January 16th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $32.67.
COPYRIGHT VIOLATION NOTICE: “Virtu Financial LLC Takes Position in Genomic Health (NASDAQ:GHDX)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/virtu-financial-llc-takes-position-in-genomic-health-inc-ghdx.html.
About Genomic Health
Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.